# AnTenGager

Type: Technology

Source: GetYourBrief — https://getyourbrief.com/entity/antengager
Canonical HTML page: https://getyourbrief.com/entity/antengager

## Timeline

- **2026-08-19**: Press Release Distribution — Company issues PRNewswire release summarizing the summit highlights.
- **2026-08-18**: Evercore Summit Presentation — Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.
- **2026-03-31**: Clinical Filings Target — Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
- **2026-03-04**: Investor Briefings — Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
- **2026-03-04**: Investor Briefings — Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.
- **2026-03-03**: Global License Agreement — Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
- **2026-03-03**: Global License Agreement — Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.
- **2026-Q1**: Regulatory Filings — Planned submission of clinical trial applications for ATG-201 in China and Australia.

## Recent coverage (4 stories, network-wide)

### Antengene Unveils 2 TCE Platforms, ATG-207 at China Summit
2026-08-23 20:02:51 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
Full story: https://gethealthbrief.com/story/antengene-tce-platforms-atg207-evercore-summit-health

### Antengene Debuts TriGager TCE and ATG-207 at 2nd Biotech Summit
2026-08-23 20:02:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
Full story: https://getbiobrief.com/story/antengene-trigager-tce-atg207-biotech-summit

### UCB and Antengene Ink $1.1B Deal for CD19 Bispecific in Autoimmune Pivot
2026-03-04 00:38:57 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
Full story: https://getbiobrief.com/story/ucb-antengene-atg201-licensing-deal-autoimmune

### UCB and Antengene Ink $1.2B Deal for Bispecific T-Cell Engager ATG-201
2026-03-04 00:38:23 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.
Full story: https://gethealthbrief.com/story/ucb-antengene-atg201-licensing-deal

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.